I’m thinking big spike...$$$$$
69danielsoneric
Posts
-
-
@ ALEXANDER ROD
I think we all know, but what’s your motive here...? Are you truly and sincerely doing us all a big favor...? I’m curious...
-
DON’T MISS the obvious here.....$$$$
EARNINGS WILL CARRY....$$$$$Q1 2019 $4,905,772 (2018 $3,179,235)
Q2 2019 $5,764,899 (2018 $3,920,566)
Q3 2019 $??.?????? This Thursday.....
Positive news from FDA, along with another strong quarter on earnings.... C’MON....!
-
Ardelyx to Host Analyst Day in New York
Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-CArdelyx logo (PRNewsFoto/Ardelyx)
NEWS PROVIDED BY
Ardelyx
Oct 10, 2019, 16:00 ET
FREMONT, Calif., Oct. 10, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an Analyst Day on Thursday, Oct. 17, 2019, from 7:30 a.m. to 11:00 a.m. ET in New York City. This year's event will focus on a review of late stage clinical development and commercial potential in hyperphosphatemia, pipeline program in hyperkalemia and the recent approval of the Company's New Drug Application for tenapanor for the treatment of IBS-C. Leading nephrologist, Myles Wolf, M.D., Chief of Nephrology, Duke University, will offer a clinician's perspective on the challenges of treating hyperphosphatemia in patients with CKD on dialysis.
CUR
ADMP
ADMP
ARDX